Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07221240 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

A Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by PRG Science & Technology Co..

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
1
Study location

NCT07221240: Recruiting Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by PRG Science & Technology Co..

NCT07221240 is a Phase 1 study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by PRG Science & Technology Co.. The registered enrollment target is 48 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07221240, a Phase 1 study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by PRG Science & Technology Co..

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The food effect will be assessed in one cohort in Part1. Approximately 48 healthy, adult subjects are planned to be enrolled in total. Subjects will participate in only one part and one cohort.

Primary Outcome

To evaluate the safety and tolerability of a single ascending dose of Amisodin in healthy adult subjects.

Interventions

  • OTHER Placebo
  • DRUG Amisodin

Study Locations (1)

Maryland

  • Pharmaron, Inc. - Baltimore

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-10-01
Est. Completion 2026-07-03
Phase Phase 1
PRG Science & Technology Co.

3 total trials

What NCT07221240 shows while recruiting

NCT07221240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07221240 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT07221240 about?

NCT07221240 is a clinical study titled "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis". Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The foo...

What is the current status of trial NCT07221240?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-10-01. Estimated completion is 2026-07-03.

What conditions does trial NCT07221240 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.

What interventions are being tested in trial NCT07221240?

The interventions under investigation include: Placebo (OTHER), Amisodin (DRUG).

Who is sponsoring clinical trial NCT07221240?

This trial is sponsored by PRG Science & Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07221240 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07221240's enrollment target sits among peer trials

48 56th of 102 higher than 47 of 102 other Amyotrophic Lateral Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07221240, the US trial registry maintained by the National Library of Medicine. NCT07221240 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.